Med Ed Report briefs

In June the University of Michigan medical school became the first in the nation to say it would stop accepting commercial support for CME courses. The school's dean, Dr. James Woolliscroft, said the university receives about $1 million a year from industry and could now ensure education is free from potential bias.

Johnson & Johnson began disclosing consulting payments to physicians made by three op-co's in its US pharma division—Centocor Ortho Biotech, Ortho-McNeil-Janssen and Tibotec. The data covers Q1 2010.

Unbound Medicine launched a mobile- and web-capable test-prep tool which allows users to build customized study aids by combining Unbound's disease, drug, and diagnostic info into virtual cards or decks. So far, Unbound has made the tool, called Grasp, available on its Nursing Central product.

ACCME said its Program & Activity Reporting System (PARS) is on track for a midsummer launch. PARS is a web-based portal designed to streamline collection of program and activity data from accredited CME providers. During a beta phase, 138 organizations tested the system and about 400 viewed educational resources, ACCME said.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.